MedTrace Logo

Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause

NCT05563675 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10011

Last updated 2025-02-19

No results posted yet for this study

Summary

To examine, among once-daily LAMA using COPD patients, whether evening administration of LAMA is superior with respect to the incidence of hospitalization requiring AECOPD or death from all causes than the more conventional morning administration.

Conditions

  • COPD Exacerbation

Interventions

DRUG

Long acting muscarinic antagonists (LAMAs) in the evening

LAMAs administered at bedtime (8pm - 2am)

Sponsors & Collaborators

  • Chronic Obstructive Pulmonary Disease Trial Network, Denmark

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-27
Primary Completion
2024-06-01
Completion
2024-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05563675 on ClinicalTrials.gov